Dacomitinib price after inclusion in medical insurance

Dacomitinib, also known as dacomitinib, is an oral, irreversible human epidermal growth factor receptor (HER) tyrosine kinase inhibitor developed by Pfizer. It was approved by the US FDA for marketing in 2018 and has become an important member of the second generation of EGFR targeted therapeutic drugs. Compared with first-generation drugs, dacomitinib exhibits stronger and longer-lasting tumor inhibitory effects due to its irreversible EGFR binding mechanism.

In clinical trials, dacomitinib is mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion mutations or exon 21 L858R substitution mutations. Its single-agent first-line treatment has shown significant efficacy in patient groups with these specific mutations, effectively delaying disease progression.

In terms of usage and dosage, the recommended dose of dacomitinib is 45 mg orally once daily. The starting dose can be adjusted to 30 mg according to the patient's condition. It is important that patients take their medication at the same time each day to ensure a stable concentration of the drug in the body.

However, the use of dacomitinib is also accompanied by a series of side effects, the most common of which include diarrhea, rash, paronychia, etc. The incidence and severity of these side effects require patients to pay close attention during treatment and communicate with their doctors in a timely manner to adjust the treatment plan.

At present, the original drug dacomitinib has been launched in the domestic market and has been successfully included in the scope of medical insurance reimbursement. Please consult the local medical insurance department for the reimbursement ratio. The original drug, 15 mg and 30 tablets, only costs more than 1,000 yuan after reimbursement by medical insurance. At the same time, Laos has generic versions of the same drug, available in 45 mg and 30 tablets. The price produced by Laos Element Pharmaceuticals is about 1,500 yuan, and that of Lucius Pharmaceuticals is about 1,200 yuan. For more price questions, please consult overseas medical consulting companies.

In general, dacomitinib has become one of the important drugs in the current field of targeted treatment of lung cancer due to its unique irreversible binding mechanism and remarkable efficacy in specificNSCLC patient groups.